Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Other Accumulated Expenses for 4 consecutive years, with $7.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Accumulated Expenses rose 280.88% year-over-year to $7.7 million, compared with a TTM value of $7.7 million through Jun 2025, up 280.88%, and an annual FY2024 reading of $216000.0, down 99.32% over the prior year.
  • Other Accumulated Expenses was $7.7 million for Q2 2025 at Atara Biotherapeutics, up from $216000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $31.8 million in Q4 2023 and bottomed at $216000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 4 years is $14.8 million, with a median of $17.9 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses tumbled 99.32% in 2024, then skyrocketed 280.88% in 2025.
  • Year by year, Other Accumulated Expenses stood at $25.0 million in 2022, then rose by 27.34% to $31.8 million in 2023, then crashed by 99.32% to $216000.0 in 2024, then surged by 3451.39% to $7.7 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ATRA at $7.7 million in Q2 2025, $216000.0 in Q4 2024, and $927000.0 in Q3 2024.